Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature
Author:
Publisher
Elsevier BV
Subject
Pulmonary and Respiratory Medicine,Oncology
Reference83 articles.
1. Less toxic chemotherapy improves uptake of all lines of chemotherapy in advanced non–small-cell lung cancer: a 10-year retrospective population-based review;Ho;J Thorac Oncol,2014
2. American Cancer Society. Lung Cancer (Non–Small Cell). Available at http://www.cancer.org/cancer/lungcancer-non-smallcell/detailedguide/non-small-cell-lung-cancer-survival-rates. Updated March 4, 2015. Accessed May 19, 2015.
3. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009
4. West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial;Mitsudomi;Lancet Oncol,2010
5. North-East Japan Study Group. Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR;Maemondo;N Engl J Med,2010
Cited by 79 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Inhibiting G6PD by quercetin promotes degradation of EGFR T790M mutation;Cell Reports;2023-11
2. Efficacy and safety of EGFR-TKIs in combination with angiogenesis inhibitors as first-line therapy for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and meta-analysis;BMC Pulmonary Medicine;2023-06-14
3. First-, Second-, and Third-Generation Radiolabeled Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Positron Emission Tomography: State of the Art, a Systematic Review;Cancer Biotherapy and Radiopharmaceuticals;2023-05-01
4. Targeting potential receptor molecules in non-small cell lung cancer (NSCLC) using in silico approaches;Frontiers in Molecular Biosciences;2023-02-09
5. Artificial intelligence in cancer imaging for diagnosis and evaluation of treatment response;Radiology Science;2022-11-23
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3